Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.

Horikawa, Reiko; Takano, Kazue; Hizuka, Naomi; Asakawa, Kumiko; Shibasaki, Tamotsu; Masuda, Akitsugu; Shizume, Kazuo

doi:10.1507/endocrj1954.33.743

Cited by 5 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The somatostatin analogue may have little influence in glucose tolerance because of its inhibitory effect on insulin secretion [21]. The balance of improving insulin sensitivity by lowering GH and decreasing insulin secretion in response to a somatostatin analogue has been suggested to influence glucose tolerance in patients with acromegaly [22]. However, another study has reported that the treatment with octreotide for 2-3 weeks did not alter the response to the 75 g oral glucose tolerance test in Japanese patients with acromegaly [23].…”

Section: Acknowledgmentsmentioning

confidence: 99%

Investigation into the Efficacy and Safety of Octreotide LAR in Japanese Patients with Acromegaly: Shizuoka Study

et al. 2009

View full text Add to dashboard Cite

Abstract. The efficacy and safety of the long-acting repeatable formulation of octreotide (OCT-LAR) treatment in patients suffering from acromegaly was investigated retrospectively in Shizuoka prefecture, Japan. Thirty patients (11 male, 19 female; average age, 48.9 years old), 29 of whom had undergone transsphenoidal surgery previously, were treated with OCT-LAR. OCT-LAR was injected i.m. every 4 weeks with an intended protocol of 20 mg over 24 months, however, 46.7% of patients required the dose of OCT-LAR to be increased. The final average dose of OCT-LAR was 25.0 ± 6.8 mg. Administering OCT-LAR significantly decreased serum GH and insulin-like growth factor 1 (IGF-1) levels (from 13.7 ± 11.9 to 5.8 ± 7.3 µg/L and from 585 ± 263 to 339 ± 193.7 µg/L after 3 months, respectively). Among patients treated with OCT-LAR, 56.7% expressed ≤2.5 µg/L serum GH and 53.3% displayed serum IGF-1 levels within the normal range, while 36.7% met both criteria that indicated treatment success. A sufficient outcome was achieved in 73.3% of patients when the rate of GH ≤2.5 µg/L or normalization of IGF-1 was accumulated. OCT-LAR did not have a negative effect on glucose tolerance when hemoglobin A1c was used as a marker. A gallbladder polyp was found only in 1 patient but it was uncertain whether OCT-LAR was involved in its development because the patient was not examined before OCT-LAR treatment. There were no abnormalities on liver function tests in any patients. In conclusion, our results showed that OCT-LAR was safe and effective as a therapeutic option for Japanese patients with acromegaly in a postoperative setting, by controlling the disease activity.Key words: Octreotide, Acromegaly, GH, Insulin-like growth factor 1 (Endocrine Journal 56: [1095][1096][1097][1098][1099][1100][1101] 2009) The mAjoriTy of patients with acromegaly suffer from pituitary adenoma, from which excessive secretion of GH induces a high incidence of pathological complications including maladaptive changes in the face and limbs, as well as diabetes mellitus, hypertension, hyperlipidemia, arteriosclerosis, and cardiovascular disorders [1]. According to a previous report, acromegaly increased the rate of mortality, while the cumulative survival rate of untreated patients was <40% over the last 20 years [2]. Observing the relationship between GH level and mortality, the 50% survival rate in three groups with GH levels of >5 μg/

show abstract

Section: Acknowledgmentsmentioning

confidence: 99%

Investigation into the Efficacy and Safety of Octreotide LAR in Japanese Patients with Acromegaly: Shizuoka Study

et al. 2009

View full text Add to dashboard Cite

show abstract

Somatostatin Analogs

2005

Acromegaly

View full text Add to dashboard Cite

A Multicenter Clinical Trial of SMS 201-995 (octreotide acetate) in Acromegaly and Gigantism

Shimatsu

Imura²,

Irie³

et al. 1989

Folia Endocrinol

View full text Add to dashboard Cite

Sixty-four patients with active acromegaly and three patients with gigantism were treated with the long acting somatostatin analog SMS 201-995 (50-500 micrograms, sc, every 6-12 h or 150-880 micrograms daily by intermittent sc infusion, for up to 114 weeks). The fasting plasma GH levels were significantly suppressed (less than 50% of the values before treatment) in 49 patients and became normal in 18 patients. Suppression of GH secretion was associated with normalization of plasma somatomedin-C levels (14 out of 30 cases) and significant clinical improvement such as disappearance of headache and decrease of excessive sweating. Shrinkage of pituitary tumors as determined by computed tomography and/or magnetic resonance imaging studies occurred in 11 out of 40 cases. Side effects were minimal and tolerable. SMS 201-995 appears to be an effective agent for the treatment of acromegaly and gigantism.

show abstract

Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.

Abstract: The effect of a long-acting somatostatin analogue SMS 201-995 on GH secretion was investigated.

Cited by 5 publications

References 14 publications

Investigation into the Efficacy and Safety of Octreotide LAR in Japanese Patients with Acromegaly: Shizuoka Study

Investigation into the Efficacy and Safety of Octreotide LAR in Japanese Patients with Acromegaly: Shizuoka Study

Somatostatin Analogs

A Multicenter Clinical Trial of SMS 201-995 (octreotide acetate) in Acromegaly and Gigantism

Contact Info

Product

Resources

About